1 Quantum Computing Stock Everyone's Ignoring While IonQ Gets the Headlines

FormFactor reported record Q2 revenue of $258.2M and highlighted a ~20% free-cash-flow margin, supported by its cryogenic testing platform used to validate superconducting and silicon-spin qubit chips. The article also points to product scaling advances (e.g., Flatiron benchtop dilution refrigerator targeting ~30 mK; expanded cryogenic cabling capacity via Delft Circuits). While IonQ’s revenue rose to $80.1M (+287% YoY), FormFactor is framed as an enabling supplier whose quantum upside may be less directly priced despite the stock being up ~270% over the past 52 weeks.

Analysis

The investable read-through is not that quantum suddenly moves FORM's P&L; it's that the company sits on the metrology toll booth if chip-based quantum ever transitions from lab science to repeatable manufacturing. That makes the revenue impact lumpy and delayed: likely negligible in the next 1-3 quarters, more meaningful only over 6-18 months if national lab funding and early fab pilots turn into repeatable orders. In the meantime, the market will probably keep valuing FORM primarily as a semiconductor test/AI-memory name, so the quantum angle is more option value than core thesis.

Competitive dynamics favor the infrastructure layer, but not all quantum names equally. FORM should benefit more than trapped-ion pure plays because its gear is architecture-agnostic for superconducting and silicon-spin paths; that said, private cryo vendors and integrated incumbents can still absorb the earliest lab and government spend, limiting near-term share gains. The second-order winner is the cabling and cryogenic ecosystem, where wiring density and thermal management become a gating constraint; that creates a potential pull-through for adjacent test and interconnect suppliers, but only if scaling programs survive beyond pilot stages.

The contrarian risk is that investors overestimate the commerciality of quantum and underestimate how much of FORM's stock is still tied to the memory/test cycle. If AI memory spending rolls over, the quantum narrative will not provide a floor. The thesis is falsified if FORM management does not show incremental cryogenic orders or if the industry pivots toward lower-cooling architectures that reduce demand for dilution refrigerators and associated test systems.

Key Decisions for Investors

• Long FORM on pullbacks only; treat quantum as free optionality, not the reason to pay up. Use a 6-12 month horizon and require evidence of booked cryogenic orders before adding size.
• Pair trade: long FORM / short IONQ over 3-6 months. The thesis is that infrastructure monetization is more durable than headline-driven cloud access announcements; cut the pair if IONQ converts partnerships into material revenue growth or FORM loses AI-memory momentum.
• Watch OXINF as a competitive read-through on cryogenic capex. If FORM wins share in national lab or university programs, consider a relative long versus other cryo incumbents; if not, the addressable quantum market likely stays too small to move the stock.
• No standalone options trade here unless FORM weakens on a memory-cycle scare. In that case, sell puts only if you are comfortable owning the semiconductor-test business, not the quantum story.